Peptide-DC-CTL (Revogene)

N/A

Report date: 2024/08/30 09:58:17

Base Information

Drug NamePeptide-DC-CTL (Revogene)
Drug Alias NameDC-CTL therapeutics (Revogene)Dendritic cell-cytotoxic T lymphocytes (Revogene)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionCytotoxic T lymphocytes replacements
TargetsUpdating
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesZhengzhou Revogene Industrial Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesZhengzhou Revogene Industrial Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A